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Background: The COVID-19 pandemic and associated non-pharmaceutical interventions (NPIs) affect health-
care seeking behaviour, access to healthcare, test strategies, disease notification and workload at public
health authorities, but may also lead to a true change in transmission dynamics. We aimed to assess the
impact of the pandemic and NPIs on other notifiable infectious diseases under surveillance in Germany.
Methods: We included 32 nationally notifiable disease categories with case numbers >100/year in
20162019. We used quasi-Poisson regression analysis on a weekly aggregated time-series incorporating
trend and seasonality, to compute the relative change in case numbers during week 202010 to 202032
(pandemic/NPIs), in comparison to week 201601 to 202009.
Findings: During week 202010 to 202032, 216,825 COVID-19 cases, and 162,942 (-35%) cases of other dis-
eases, were notified. Case numbers decreased across all ages and notification categories (all p<005), except
for tick-borne encephalitis, which increased (+58%). The number of cases decreased most for respiratory dis-
eases (from -86% for measles, to -12% for tuberculosis), gastro-intestinal diseases (from -83% for rotavirus
gastroenteritis, to -7% for yersiniosis) and imported vector-borne diseases (-75% dengue fever, -73% malaria).
The less affected infections were healthcare associated pathogens (from -43% infection/colonisation with car-
bapenem-non-susceptible Acinetobacter, to -28% for Methicillin-resistant Staphylococcus aureus invasive
infection) and sexually transmitted and blood-borne diseases (from -28% for hepatitis B, to -12% for syphilis).
Interpretation: During the COVID-19 pandemic a drastic decrease of notifications for most infectious diseases
and pathogens was observed. Our findings suggest effects of NPIs on overall disease transmission that require
further investigation.
Funding: The Robert Koch Institute is the National Public Health Institute of Germany, and is an institute
within the portfolio of the Federal Ministry of Health.
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Impact of the COVID-19 pandemic and associated non-pharmaceutical interventions on other
An analysis of national surveillance data during week 12016  week 322020, The Lancet
.org/10.1016/j.lanepe.2021.100103Introduction
In response to the Coronavirus disease 2019 (COVID-19) pan-
demic, public health authorities and healthcare providers have had
to prioritise their work towards COVID-19 management, since the
beginning of 2020. During peak incidence of COVID-19 cases, health-
care providers have often deprioritised elective healthcare [1], or
switched to virtual consultations if possible. In addition, healthcareseeking behaviour has changed drastically, as shown by drops in GP
and emergency department attendances [2], and fewer hospital
admissions for acute coronary syndrome [3]. These changes in
healthcare seeking behaviour are likely to be multifactorial, and
could potentially be due to reluctance to attend health-facilities
because of concerns of catching COVID-19. In Germany, following
the initial containment of a cluster of COVID-19 cases starting at the
end of January 2020 [4], sustained transmission of SARS-CoV-2 com-
menced end of February 2020, followed by implementation of
the first national public health measures (i.e. non-pharmaceutical
interventions, NPIs) in March 2020, as described with more detail in
the Box.
Research in context
Evidence before this study
We conducted a PubMed search for titles and abstracts includ-
ing the search terms (''COVID-1900 [Supplementary Concept])
AND ''Population Surveillance''[Mesh] AND ''prevention and
control'' [Subheading] as well as ''non-pharmaceutical inter-
vention*'' from database inception to 19 November 2020. In
addition, we reviewed the references of relevant studies. Stud-
ies on the impact of the COVID-19 pandemic and its associated
non-pharmaceutical interventions (NPIs) on routine infectious
disease surveillance were scarce and mostly limited to influ-
enza and other respiratory illnesses during the first wave of
COVID-19. Typically, public health research on NPIs focused
solely on their impact on COVID-19 transmission. However, a
decrease in healthcare utilisation during the first months of the
pandemic has been documented in different settings (emer-
gency department visits, hospital admissions, primary care)
and for a number of non-communicable diseases (including
cardiovascular disease, psychiatric emergencies).
Added value of this study
To our knowledge, this study is the first to examine the impact
of the COVID-19 pandemic and associated NPIs on the full spec-
trum of infectious diseases under national surveillance. We
showed a significant decrease of notifications for almost all
notifiable diseases during the COVID-19 pandemic compared to
previous years, taking seasonality and trends over time into
account. The reason for this changing dynamic is multifactorial,
including a reduction in healthcare utilisation, and reduced
transmission due to NPIs and changes in mobility.
Implications of all the available evidence
The changes in health care utilisation behaviour as well as
decreasing cases of infectious and non-communicable diseases
show the massive impact that the COVID-19 pandemic and its
associated NPIs had, and continues to have, on our societies
and health systems worldwide. Surveillance systems face the
challenge of dealing with variances in case numbers and identi-
fying appropriate references for all infectious diseases, under
these unprecedented circumstances. Despite the dominance of
COVID-19 surveillance, other infectious disease must not be
overlooked. Changes in transmission patterns but also underdi-
agnosis and changes in healthcare utilisation behaviour must
be monitored closely and call for alignment of public health
measures. Vigilant and consistent infectious disease surveil-
lance as well as further research is required to better under-
stand the reasons behind those causal dynamics and to
anticipate structural changes affecting routine surveillance.
Box. Timeline of the COVID-19 epidemic and associated non-
pharmaceutical interventions in Germany, January-August
2020
In Germany, following the initial containment of a cluster of
COVID-19 cases starting at the end of January 2020 [4], commu-
nity transmission of SARS-CoV-2 commenced end of February
2020, following the introductions of cases from Italy and Aus-
tria (often related to people returning from ski holidays), and
clusters of cases associated with carnival celebrations and other
mass gathering events [37]. On 10 March 2020 (week 11-2020),
initial measures (i.e. non-pharmaceutical interventions, NPIs)
banning mass gatherings started, followed by gradual closing of
schools and day care facilities, and a world-wide non-essential
travel ban. On 23 March 2020 (week 13-2020), strict physical
distancing measures were put in place on a national level
(“lockdown”): contact with one other person outside of one’s
household was allowed. Shops, restaurants, hairdressers and
other salons requiring close physical contact were closed; being
outside for grocery shopping, medical appointments and sports
was permitted. In addition, international travel restrictions and
quarantine measures for those entering Germany were put in
place for those traveling from areas with high COVID-19 rates.
On 20 April 2020, the first loosening of measures started, by
allowing shops of certain sizes to reopen, followed by allowing
for larger (though restricted) numbers of people to gather. Dif-
ferent levels of contact restrictions, promotion of hand-hygiene,
and the use of face masks in closed (public) spaces such as pub-
lic transport, stores and the workplace, remained in place till
the end of the observational period (week 32-2020) [38].
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NPIs on the (public) health system have largely focussed on COVID-
19 transmission (Research in Context). However, changes in case
notifications of other infectious diseases under surveillance have
been observed, particularly for respiratory infections [5] and sea-
sonal influenza [6-9], but also for measles [10]. These changes
could have been related to differences in healthcare seeking
behaviour, access to healthcare, test strategies, alternations in dis-
ease notification and workload at public health authorities, but
may be also driven by a true change in transmission dynamics,
initiated by the NPIs.Please cite this article as: A. Ullrich et al., Impact of the COVID-19 pa
notifiable infectious diseases in Germany: An analysis of national surv
Regional Health - Europe (2021), https://doi.org/10.1016/j.lanepe.2021.10To understand the epidemiology of all infectious diseases under
surveillance during the pandemic, we aimed to assess the impact of
the COVID-19 pandemic and NPIs on notifiable infectious diseases
under surveillance in Germany.
Methods
Design & setting
We analysed data from the reporting system for surveillance of
notifiable infectious diseases in Germany [11, 12]. As of 1 January
2001, the Protection Against Infection Act determines which infec-
tious diseases (x6, notifications by medical doctors) and which
detected pathogens (x7, notifications by laboratories) are notifiable
[13]. Case definitions define epidemiological, clinical and laboratory
criteria for each notifiable disease [14]; COVID-19 was added as a
notifiable disease in Germany on 1 February 2020.
Clinicians and laboratories report cases of infectious diseases and
pathogen detection to local health authorities in 412 counties, from
where they are forwarded via the state public health authority to the
Robert Koch Institute (RKI, national public health institute), except
for the detection of HIV, Treponema pallidum (syphilis) and Plasmo-
dium spp. (malaria) which are reported by laboratories directly to
RKI. The RKI provides an overview of the epidemiology of all notifi-
able diseases in Germany on a regular basis [15].
Data source & inclusion criteria
Case information was retrieved from the notifiable disease data-
base at RKI. We included disease categories that are notifiable in all
federal states, with a date of notification between 1 January 2016
(week 012016) and 9 August 2020 (week 322020). We excluded
disease categories with <100 cases per year in 20162019 (i.e. Zika
virus disease, Chikungunya virus disease, Leptospirosis, Rubella,ndemic and associated non-pharmaceutical interventions on other
eillance data during week 12016  week 322020, The Lancet
0103
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by week was not suitable for small case numbers, nor was it of inter-
est to study the relationship between the pandemic, NPIs and dynam-
ics on relatively rare diseases. Additionally, hantavirus disease,
adenovirus conjunctivitis and invasive pneumococcal diseases were
excluded due to complex epidemiological dynamics, changes in case
definitions, or very limited time under surveillance. Included and
excluded disease categories and their reason for exclusion are sum-
marised in Supplemental Table 1.
Variables & definitions
For each notification, we extracted the date of notification, date of
disease onset, age, sex, county, state notification category, and case
definition from the notifiable disease database as of 8 November
2020.
We grouped the included notification categories into five main
groups: One, respiratory diseases (including vaccine-preventable and
childhood-related diseases), including chickenpox, invasive Haemo-
philus influenzae infection, seasonal influenza, legionellosis, measles,
invasive meningococcal disease, mumps, whooping cough, and
tuberculosis. Two, gastro-intestinal diseases, including, Campylobac-
ter-enteritis, cryptosporidiosis, enterohemorrhagic Escherichia coli
(EHEC)-disease, giardiasis, hepatitis A, hepatitis E, listeriosis, norovi-
rus gastroenteritis, rotavirus gastroenteritis, salmonellosis, shigello-
sis, yersiniosis. Three, cases of healthcare associated pathogens,
including Clostridioides difficile infections with a severe clinical
course, infection or colonisation with carbapenem-non-susceptible
Acinetobacter (CRA) and Enterobacterales (CRE), and invasive infec-
tion with Methicillin-resistant Staphylococcus aureus (MRSA). Data
for the disease categories C. difficile, CRA and CRE were only available
from 1 January 2017 onwards. Fourth, sexually transmitted and
blood-borne diseases, including hepatitis B, and C, HIV infection, and
syphilis. For hepatitis B and C, cases were included from 1 January
2018 onwards, due to changes in case definitions. Fifth and last, vec-
tor-borne diseases (endemic & imported), including tick-borne
encephalitis (TBE), dengue fever, and malaria.
Ethics statement
Pseudonymized notification data was collected at the RKI based
on the German Infection Protection Act [13].
Statistical methods
We assessed the impact of the COVID-19 pandemic and associated
NPIs on case notification of other notifiable infectious diseases using
two statistical approaches described in detail below. First, we calcu-
lated the overall and age-stratified change in case notifications for all
notifications combined (except for COVID-19) for the weeks 10 to 32
in 2020, compared to the same weeks in 20162019. Second, we cal-
culated disease-specific estimates based on weekly aggregated
times-series using the full observation period.
First, we determined the overall change in notification numbers
amongst all notification categories (except COVID-19) during the
reporting week 1032 for the years 2016 to 2020 using negative
binomial regression. The regression model included notification
numbers (count) and a binary pandemic variable, which was set to 1
for the pandemic year (2020) and 0 for all other years (2016, 2017,
2018, 2019); see Eq. (1). There was no apparent trend amongst over-
all notification numbers. Seasonality was implicitly modelled through
the data selection on a specific time period of the year, i.e. week
1032. In practice, the exponential of the regression coefficient of
the binary pandemic variable represented the change in notification
numbers during the pandemic year 2020, compared to the numbers
in previous years. I.e., the exponential of the regression coefficientPlease cite this article as: A. Ullrich et al., Impact of the COVID-19 pa
notifiable infectious diseases in Germany: An analysis of national surv
Regional Health - Europe (2021), https://doi.org/10.1016/j.lanepe.2021.10(exp(b1)) of 0.65 meant that notification numbers were only at a level
of 65% of the expected numbers based on previous years, in turn
meaning a 35% decrease in notifications. Confidence intervals for the
regression coefficient were derived by profiling of the likelihood
function, the 95% confidence interval (95%CI) was reported. The same
analysis was performed for each of the six age groups 04 years,
514 years, 1534 years, 3559 years, 6079 years and 80+ years.
log E countð Þð Þ ¼ aþ b1 pandemicð Þ ð1Þ
Second, to determine the relative change in notification numbers
for each specific notification category, we used a quasi-Poisson
regression analysis on a weekly aggregated time-series (date of noti-
fication). This regression model (Eq. (2)) incorporated variables for
trend, seasonality, and a binary pandemic variable (analogous to the
model above: 1 for pandemic reporting weeks 202010 to 202032,
and 0 for all other weeks, i.e. 201601 to 202009). From the expo-
nential of the regression coefficient (b1Þ for the binary pandemic var-
iable, we derived the relative difference between the expected
number of notifications based on notifications in previous years and
the actual number of notifications during the COVID-19 pandemic
(week 202010 to 202032). The relative change per week was
computed based on the difference between the actual number of
notifications for one week and the expected value for the same week,
under the assumption that no pandemic or NPIs were present (week
201601 to 202009). This expected value, the difference, and
95%CI, were computed for the weeks from 2020 to 01 to 202032.
log E countð Þð Þ ¼ aþ b1 pandemicð Þ þ b2 trendð Þ
þ b3 sin 2p  week=52ð Þ þ cos 2p  week=52ð Þð Þ
ð2Þ
In addition, we investigated whether the overall change (in %) in
notification numbers amongst all other disease categories was associ-
ated with the COVID-19 case load. To this end, we computed the
overall change in notifications (all disease categories except COVID-
19) and the number of COVID-19 cases (absolute, and as cases per
100,000 inhabitants) for each of the 412 counties. We computed the
Pearson correlation and used the t-test statistic to test for a linear
relationship between the overall relative change and the COVID-19
incidence, the number of cases and the population, respectively. Cor-
relations were considered statistically significant, when p < 0.05. All
data analysis was performed in R (Version 3.6.1); using the dplyr,
tidyr,MASS, stats, ggstatsplot, ggplot2 packages.Role of the funding source
The Robert Koch Institute is the National Public Health Institute of
Germany, and is an institute within the portfolio of the Federal Minis-
try of Health. The funders had no role in study design, data collection,
data analysis, interpretation, writing of the report.Results
All notifiable diseases in Germany, including COVID-19
We included 32 nationally notifiable disease categories that had
reported on average >100 cases per year before the COVID-19 pan-
demic and NPIs started (Supplemental Figure 1). Between week 10
and 32 in 2020, 379,767 cases were reported to RKI, of whom the
majority (n = 216,825; 57%) were COVID-19 cases. During the same
period, 162,942 cases of all reported infectious diseases (except
COVID-19) were recorded, which was 35% (95%CI: 58%; 2%)
compared to previous years same time period (2016: 219,752; 2017:
195,776; 2018: 344,636; 2019: 247,692), irrespective of disease cate-
gory. There was no statistically significant correlation between thendemic and associated non-pharmaceutical interventions on other
eillance data during week 12016  week 322020, The Lancet
0103
Fig. 1. Relative change (%) in the number of cases in different age groups during the
first months of the COVID-19 pandemic and non-pharmaceutical interventions, com-
pared to the expected number of cases.
* Statistically significant changes (p<0.05): 04 years 57% (95%CI: 66%; 45%);
514 years 47% (95%CI: 61%; 29%), 1534 years 24% (95%CI: 45%; 4%),
3559 years 24% (95%CI: 59%; 41%), 6079 years 32% (95%CI: 61%; 19%), 80+
years 43% (95%CI: 64%, 9%).
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of cases for all other infectious diseases. Neither the COVID-19 case
load or incidence, nor population size of the county was associated
with the overall decrease in case numbers (Supplemental Figure 2).
Case numbers seemed to decrease across all ages, with the largest
and statistically significant decreases observed amongst those under
14 years of age (04 years 57% [95%CI: 66%; 45%]; 514 years
47% [95%CI: 61%; 29%]) and over 80 years of age (43% [95%CI:
64%, 9%]) (Fig. 1). No difference in overall change in the number
of cases were found by sex. All disease categories changed signifi-
cantly compared to previous years (p-value < 0.05) (Table 1). Case
numbers decreased across all notification categories ranging from
83% to 7%, except for TBE, which increased +58%.
Respiratory diseases
All included respiratory diseases showed a substantial and statis-
tically significant reduction of cases during the first months of the
pandemic and NPIs (range: 855% to 116%), compared to the
expected number of cases. The largest decrease was observed for
measles, which decreased by 855% (95%CI: 890%; 810%,
Fig. 2A). Whooping cough also showed a large decrease in cases
(637% [95%CI: 652%; 622%], Fig. 2B), followed by invasive
Haemophilus influenzae infection (61.3% [95%CI: 674%; 542%]),
seasonal influenza (544% [95%CI: 549%; 539%], Fig. 2C),
chickenpox (515% [95%CI: 530%; 500%], Fig. 2D), invasive
meningococcal disease (471% [95%CI: 552%; 376%]), and
mumps (333% [95%CI: 428%; 221%]). Legionellosis cases
decreased by 278% (95%CI: 342; 207), and tuberculosis cases
by 116% (95%CI: 116; 66, Fig. 2E).
Gastro-intestinal diseases
All included gastro-intestinal diseases showed significant reduc-
tions in cases (range: 833% to 70%), compared to the expected
number of cases based on previous years. The largest decreases were
seen amongst rotavirus disease (833% [95%CI: 839%; 827%],
Fig. 2F), shigellosis (829% [95%CI: 870%; 776%]), and norovi-
rus disease (787% [95%CI: 792%; 782%], Fig. 2G). Case num-
bers of cryptosporidiosis (524% [95%CI: 572%; 470]), EHEC-
Please cite this article as: A. Ullrich et al., Impact of the COVID-19 pa
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Regional Health - Europe (2021), https://doi.org/10.1016/j.lanepe.2021.10disease (464% [95%CI: 509%; 415%]), salmonellosis (455%
[95%CI: 474%; 434%]), giardiasis (433% [95%CI:
473%;390%]), hepatitis A (367% [95%CI: 435%; 291%]),
Campylobacter-enteritis (222% [95%CI: 234%; 210%], Fig. 2H),
and listeriosis also showed substantial decreases. Hepatitis E (70%
[95%CI: 109%; 30%]) and yersiniosis (70% [95%CI: 135%;
00%]) were also reported less frequently than expected.
Healthcare associated pathogens
The number of cases of all pathogens in this category showed an
overall substantial and statistically significant reduction (range:
427% to 280) during the first months of the pandemic and NPIs,
compared to the expected number of cases based on previous years:
CRA 427% (95%CI: 520%; 316%), C. difficile infections with a
severe clinical course 324% (95%CI: 375%; 246%), CRE
346% (95%CI: 386%; 302%, Fig. 2I); and MRSA invasive infec-
tion 280 (95%CI: 346%; 207%).
Sexually transmitted and blood-borne diseases
During the first months of the pandemic and NPIs, the expected
number of hepatitis B and hepatitis C cases decreased by 283%
(95%CI: 320%; 244%) and 277% (95%CI: 318%; 234%)
respectively, compared to the expected number based on notification
data from 2018 to 2019. HIV cases decreased by 221% (95%CI:
276%; 161%), and syphilis by 121% (95%CI: 158%; 82%),
compared to expected number of cases, based on 20162019.
Vector-borne diseases
The number of dengue fever cases decreased substantially by
751% (95%CI: 795%; 699%, Fig. 2K), compared to the expected
number of cases. Likewise, the number of malaria (Plasmodium spp.)
cases decreased by 730 (95%CI: 777%; 674%).
TBE was the only notification category that showed a significant
increase in case numbers during the first months of the pandemic
and NPIs, compared to the expected number based on previous years:
+577% (95%CI: +378%; +805%, Fig. 2J).
Discussion
During the first months of the COVID-19 pandemic and NPIs in
Germany, an extensive change in cases of infectious diseases under
routine national surveillance was observed. COVID-19 dominated
infectious disease surveillance: more than half of the total reported
cases were COVID-19. In parallel, a large decrease in case numbers
for nearly all infectious diseases was recorded, especially amongst
younger and older age groups, except for TBE, for which we observed
a notable increase in case numbers.
The reasons behind this drastic change in notification dynamics
are multifactorial, and cannot be fully explained by our analysis of
routine surveillance data; the current analysis is subject to limitations
summarised here and alongside the disease-group specific discus-
sion. We could not take the perceived health and healthcare seeking
behaviour into account, which to a large extent influence subsequent
diagnosis and reporting. By close collaboration with all public health
specialists responsible for the routine monitoring and surveillance of
these pathogens, we aimed to increase our awareness of all possible
factors that might influence or bias these findings in this discussion.
In general, the notification system depends on diagnosis of infectious
diseases by physicians and laboratories. Therefore, health care seek-
ing behaviour and the number of laboratory tests conducted play an
important role for capturing a case in the system. Further investiga-
tion of the full cascade of care is needed to understand if and to what
extent underdiagnosis played a role in the decrease in notifications.ndemic and associated non-pharmaceutical interventions on other
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Fig. 2. Temporal variation in case numbers notified in week 1 to 32 in 2020, compared to the expected case numbers, of a selection of infectious diseases under surveillance in
Germany.
CRE = Enterobacterales, carbapenem-non-susceptible, TBE = tick-borne encephalitis. The number of expected cases was estimated with quasi-Poisson regression analysis, using
case data of week 201601 to 202009. The regression model incorporated trend and seasonal components.
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reported a decrease in the number of samples being sent to laborato-
ries, which ruled out potential de-prioritisation or delays because ofPlease cite this article as: A. Ullrich et al., Impact of the COVID-19 pa
notifiable infectious diseases in Germany: An analysis of national surv
Regional Health - Europe (2021), https://doi.org/10.1016/j.lanepe.2021.10an increase in samples for SARS-CoV-2 diagnostics at laboratories
[16]. We found no significant correlation on county level between
reported COVID-19 cases and overall decrease of notification for thendemic and associated non-pharmaceutical interventions on other
eillance data during week 12016  week 322020, The Lancet
0103
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circulating virus strains (e.g. seasonal influenza, rotavirus), multi-
annual seasonality (e.g. measles, TBE) and large outbreaks (which can
affect both the size of the susceptible population over time, as well as
the case numbers), could not be accounted for in the current analysis,
and may have introduced bias. In addition, various infectious diseases
follow mixed patterns of transmission. For example, hepatitis A can
be both food-borne, transmitted from person-to-person, as well as
travel-associated. These dynamics cannot be untangled in this study.
Moreover, the observation time is too short to monitor dynamics in
transmission of pathogens with long incubation times (e.g. tuberculo-
sis, hepatitis B and C, HIV). Of note, we also limited our current analy-
sis to diseases under national surveillance, i.e. excluding diseases that
are notifiable in a selection of states such as Lyme disease, chlamydia,
and hand, foot, and mouth disease.
NPIs, including school closures, physical distancing, and enhanced
hand-hygiene, likely resulted in a reduction in transmission of respira-
tory diseases included in our analysis. The large drop in measles cases,
while being in-season, is striking, and likely to be multicausal. Measles
outbreaks in Germany usually start with a travel-associated introduc-
tion, followed by outbreaks, which were less likely to occur due to bor-
der closure and travel restrictions. A recent analysis of measles
surveillance indicated drops in reported case numbers across the EE/
EEA and UK till May 2020, which could be due to underdiagnosis,
underreporting, but potentially also a reduction in circulation [10]. A
reduction in transmission and, to a lesser extent, a potential reduction
in presentation to care and underdiagnosis are considered the main
reasons for the decrease of measles case numbers. Lack of laboratory
capacity and a potential backlog in notifications have been rather ruled
out by state health authorities [personal communication: Dorothea
Matysiak-Klose, RKI, infectious disease epidemiology, vaccine prevent-
able diseases] and the national reference centre [personal communica-
tion: Annette Mankertz, RKI, national reference centre for measles,
mumps, rubella]. In addition to measles, the NPIs physical distancing,
school and day-care closures, and face masque wearing, have reduced
the likelihood of transmission of many vaccine-preventable and child-
hood associated infections with droplet/airborne transmission, includ-
ing pertussis, invasive Haemophilus influenzae infection, chickenpox,
invasive meningococcal disease, and mumps.
The impact of the first months of the COVID-19 pandemic and
NPIs on seasonal influenza during the observation period is multifac-
torial. First, the 2019/2020 influenza season was assessed to be mod-
erate compared to previous seasons, and was close to its end when
the COVID-19 pandemic started [17]. Second, influenza notifications
are influenced by testing behaviour for influenza and other respira-
tory diseases, which in turn were affected by the severity of (current
and previous) influenza seasons on the one hand, and by testing
behaviour for COVID-19 on the other. Alterations in notification data
therefore do not directly translate into a change in the underlying
epidemiology. Nonetheless, the influenza season abruptly ended
about two weeks earlier than expected, as confirmed by syndromic
and virologic surveillance systems for acute respiratory illness [17-
19]. NPIs aiming to prevent transmission of COVID-19 are likely to
have prevented transmission of seasonal influenza as well. Decreased
influenza activity during the COVID-19 pandemic was reported in
several countries in both the northern and southern hemisphere,
where its decrease was associated with COVID-19 infection preven-
tion measures [6, 9, 20, 21].
A reduction in case numbers of gastro-intestinal diseases was
observed across all age groups. NPIs for COVID-19 including
enhanced hand-hygiene, closure of day care facilities and home office
work also prevent human-to-human transmission of gastro-intesti-
nal infections. Travel restrictions prevented importation of cases
from endemic countries. Even though there was a change in eating
habits (i.e. people ate less often in restaurants and more at home),
people remained at risk for food-borne infections. This supports thePlease cite this article as: A. Ullrich et al., Impact of the COVID-19 pa
notifiable infectious diseases in Germany: An analysis of national surv
Regional Health - Europe (2021), https://doi.org/10.1016/j.lanepe.2021.10hypothesis that the reduction in case numbers is also related to
under-diagnosis, due to a change in healthcare utilisation behaviour
[16, 22, 23].
Notifications of the healthcare associated pathogens C. difficile
infection with a severe clinical course, CRA, CRE, and MRSA decreased
by about one third. This reduction might be due to COVID-19 related
increased infection prevention and control measures within hospi-
tals. The cancellation and rescheduling of many elective procedures,
and a reduction in overall healthcare utilisation, have led to a reduc-
tion in absolute patient numbers [1, 2] and therefore a reduction of
these infections and pathogens. Antimicrobial resistant pathogens
could either increase or decrease during the COVID-19 pandemic, in
particular antibiotic prescribing and infection prevention and control
practices [24]; the impact of the pandemic on antimicrobial resis-
tance will only become clear in the coming months and years as data
gradually become available. In the long run, it is expected that the
impact of the COVID-19 pandemic is more likely to increase the
development of antimicrobial resistance, due to overuse of antibiot-
ics, wide use of biocidal agents for environmental and personal disin-
fection, and disruption of health services and treatment [25].
Case numbers of sexually transmitted and blood-borne infections
with hepatitis B and C, HIV, and syphilis have all decreased during the
first months of the COVID-19 pandemic. Interpretation of this reduc-
tion is challenging for several reasons. Caution is warranted when
interpreting notification data over time, because of a short reference
period, and recent changes in the hepatitis B and C case definitions
[26, 27]. Furthermore, case notification of HIV and syphilis follows an
ongoing process of laboratory-based anonymous reporting, which is
supplemented by clinical data of medical doctors, followed by dedupli-
cation on national level. Therefore, the set of HIV and syphilis of case
notifications included in this analysis (throughout the course of 2020)
might include a slightly different set of cases than the annual data lock
presented for yearly reporting [15]. Additionally, diagnosis of these
infections often occurs in the chronic stage of disease.
Behaviour plays a large role in sexually transmitted and blood-
borne infections. A Dutch survey indicated that singles were dating
less, and had less partners during the pandemic, related to contact
reduction, and closure of nightclubs and bars [28], which could in
turn have led to a reduction in STI transmission. An ad-hoc survey
amongst users of the gay dating platform GayRomeo (predominantly
from Germany) in early April 2020 showed a dramatic reduction of
partner seeking [29], and HIV-PrEP uptake monitoring showed a
strong transient reduction of first PrEP uptake visits during the sec-
ond quarter of 2020. Conversely, the reduction in notifications could
also be a result of a reduction in healthcare seeking behaviour. Impor-
tantly, de-prioritisation and interruptions of sexual health service
provision has challenged access to testing facilities [30]. A recent
survey amongst German Hepatitis C-Registry centers showed a
decrease of consultations of hepatitis C patients and delayed diag-
noses during lockdown regulations in the first COVID-19 wave,
which may support this finding [31]. Local health authorities
often had to de-prioritise these services due to a focus on the
pandemic response. Furthermore, the closure of low-threshold
facilities has put injecting drug users at higher risk of infection
[32], which is of concern. Without adequate service provisions,
sexually transmitted and blood-borne infections can remain
undetected, and might in turn lead to increase in spread.
Travel restrictions and border closure prevented new importation
of infectious diseases that are not endemic in Germany, which had a
direct effect on dengue fever and malaria notifications. Most cases
notified during the early pandemic phase likely resulted from pre-
pandemic travel. In addition, travel restrictions have prevented
imported cases of gastro-enteritis (e.g. hepatitis A, giardiasis, crypto-
sporidium). Despite their respiratory transmission routes, the reduc-
tion in cases of measles, legionellosis and tuberculosis in Germany
are also likely to be due to a reduction in mobility because of travelndemic and associated non-pharmaceutical interventions on other
eillance data during week 12016  week 322020, The Lancet
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likely a consequence of a reduction in respiratory transmission.
Imported measles cases were the main reason for regional outbreaks
in recent years [15].
The only increase in case numbers was observed for TBE. The
increase was substantial, though likely to be multifactorial. One factor
could be increased engagement in outdoor activities in endemic areas
in Germany, because other recreational activities were limited due to
the public health measures. However, the increase may also be related
to high tick counts, as observed in 2020 in several regularly flagged
areas, as well as a higher proportion of adult ticks, which have a higher
TBE virus prevalence than the younger tick stadia [personal communi-
cation: Gerhard Dobler, German TBE consultant laboratory]
The multicausality behind these dynamics in disease notifica-
tions cannot be fully explained, and highlights the need for vigi-
lant infectious disease surveillance, during the protracting
emergency of COVID-19. At the same time, the use of routine sur-
veillance data is a strength, as this enables long term assess-
ments, comparisons with routine notification data in other
systems, and can contribute to future preparedness and response.
A true potential reduction in transmission of infectious diseases
under these NPIs is reassuring in terms of effectivity of the meas-
ures to prevent infectious disease transmission, which reduces
the burden of disease in the population, as well as the burden on
the healthcare system. However, potential underdiagnosis of
infectious diseases is of concern. Future analyses of the data will
provide more insight into long-term effects of the pandemic and
NPIs on the healthcare system and disease transmission. In addi-
tion, future evaluations will be able to indicate whether or not
fundamental changes will occur.
Public health communication should highlight safety and accessi-
bility of all preventive and clinical health services, and urge people to
seek healthcare when needed. In addition, preventive health services
for all infectious diseases, such as vaccination and sexual health serv-
ices, and low-threshold facilities for injecting drug users, should
remain operational as much as possible, and known to be safe and
accessible to the public. Importantly, the observed increase in TBE
notifications warrants enhanced prevention and control measures
adapted to increased outdoor activity, by raising awareness through
communication, and vaccination for those at risk, i.e. people living in
or visiting TBE endemic areas. Public risk perception of all infectious
diseases, and its associated prevention measures, are dynamic and
closely monitored to allow swift adaptation to ensure long-term trust
in public health authorities [34]. Importantly, the COVID-19 pan-
demic amplifies socioeconomic inequalities in health, putting those
with lower socio-economic status at higher risk for COVID-19, as well
as other communicable and non-communicable public health threats
[35, 36].
In conclusion, the COVID-19 pandemic and its associated NPIs
have drastically affected infectious disease notifications and surveil-
lance, during the first months of the pandemic. Notification data
depend on the actual number of infections, healthcare seeking behav-
iour, diagnosis, and subsequent reporting. The primary public health
measures for COVID-19 in Germany, i.e. the NPIs physical distancing,
hand and cough hygiene, face masks and ventilation, aim for a reduc-
tion in human-to-human transmission of infectious diseases, espe-
cially respiratory infections through droplets. The collateral effect of
these interventions may have resulted in an overall reduction in
transmission for some other infectious diseases. However, caution is
warranted because the reduction in notifications does not necessarily
mean a reduction in transmission.
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